In addition, p-ERK promoted cisplatin resistance in ovarian tumors through stabilizing HIF-1α by phosphorylating PHD2, an enzyme hydroxylating HIF-1α and inducing its degradation by a ubiquitin-mediated pathway (Li et al., 2019). The gene discussed is HIF1A; the disease is ovarian neoplasm.